SVNT's orphan gout therapy Krystexxa has no efficacy problem
It's already approved and SVNT is presently expanding its use into severe Dialysis patients and for Induction therapy. Read the article about Pegloticase(Krystexxa) being used as an Induction Therapy for gout patients with severe tophi. Dr Robert Wortmann safely and successfully uses Induction therapy for his patients. Krystexxa is already approved in the US and is expected to receive EU approval next month. Peak world revenue estimates for Krystexxa will reach about $500-$600 mil after SVNT enters the dialysis & induction mkt. Like QCOR & JAZZ, SVNT will also trade between 5-7x sales and have a mkt cap of around $2 bil once profitable. SVNT's mkt cap is currently only "$96 mil ". A $2 bil mkt cap would send SVNT's share price to $28/sh. Finally, check out SVNT's extremely bullish Jan 2013 Call/Put Ratio. Good luck to all.